October 10, 2025 — Leads & Copy — American Oncology Network (AON) announced that 15 research abstracts by AON physicians and leaders have been accepted for presentation at the American Society of Clinical Oncology (ASCO) Quality Care Symposium 2025. The event, themed Driving Solutions, Implementing Change, takes place Oct. 10-11 in Chicago.
AON leaders will present on topics including the Inflation Reduction Act’s influence on Enhancing Oncology Model (EOM) Part D expenditures and total cost of care (Abstract #2) and Inflation’s Toll on Oncology Physician Reimbursement (Abstract #21).
A full list of AON physician and leader abstracts at the ASCO Quality Care Symposium include:
Navigating New Norms: The Inflation Reduction Act’s Influence on Enhancing Oncology Model Part D Expenditures and Total Cost of Care (Abstract #2)
The Shrinking Dollar: Inflation’s Toll on Oncology Physician Reimbursement (Abstract #21)
Unpacking Cost of Care: Contributors to Total Cost of Care in Oncology Episodes (Abstract #22)
The Impacts of Medicare Biosimilar Reimbursement Policies (Abstract #25)
Rethinking Infusion Staffing Metrics to Address the Complexity of Modern Hematology-Oncology Therapies (Abstract #62)
Balancing Case Mix Risk: The Role of Cancer Type Mix on Savings in Total Cost of Care Models (Abstract #82)
Minimum Episode Volume to Reduce Stochastic Risk in the Enhancing Oncology Model (Abstract #89)
Assessing Episode Groupers Impacting Cost & Quality Comparisons in the Enhancing Oncology Model (Abstract #90)
Where You Live Matters: Unpacking the Geography of Deprivation in Oncology Care (Abstract #234)
Rethinking Systematic Anti-Cancer Therapy in the Last 14 Days of Life in the Era of Oral Oncology (Abstract #466)
Clinical Adjusters in the EOM Can be Derived From Claims Rather Than Practice-Reported (Abstract #87)
The Impact of Applying Clinical Adjusters via Histology to Lung Cancer in the EOM (Abstract #88)
Impact of State Medicaid Expansion on Practice Performance in the Enhancing Oncology Model (Abstract #196)
Clinical Outcomes for Patients Treated with Pembrolizumab Weight-Based Dosing in the Enhancing Oncology Model (Abstract #27)
Clinical Adjusters in the EOM Should Not be Static: a deep dive into HER2 (Abstract #86)
Puneeth Indurlal, MD, AON’s senior vice president, said ASCO symposiums foster collaboration and innovation.
Dr. Stephen “Fred” Divers, AON’s chief medical officer, said the studies demonstrate the combination of real-world clinical data and robust technology to harness it for the creation of value-based insights.
Todd Schonherz, AON’s chief executive officer, said AON’s culture of innovation and learning is supporting ASCO in advancing the field of oncology.
Contact:
Karen Riley Sawyer
American Oncology Network
Karen.Sawyer@AONcology.com
Source: American Oncology Network
